Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo

Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate in combination with Tagrisso (osimertinib) in a ... Read More